Condition: Thyroid Eye Disease · Sponsor: Amgen
The main objective of this trial is to assess the efficacy of AMG 732 in participants with thyroid eye disease (TED) who are defined as primary nonresponders or relapsed during the safety follow-up in the parent trial (NCT06401044).
This description comes directly from the study's public registry record.
Amgen Call Center · 866-572-6436 · medinfo@amgen.com
Always discuss trial participation with your own doctor first.
| Applied Research Center of Arkansas | Little Rock, Arkansas, United States | Recruiting |
| Ilumina Medical Research | Kissimmee, Florida, United States | Recruiting |
| Vision Medical Research, Inc. | Orland Park, Illinois, United States | Recruiting |
| West Virginia University | Morgantown, West Virginia, United States | Recruiting |
| Eb Group Spolka z ograniczona odpowiedzialnoscia | Warsaw, Poland | Recruiting |
| Hospital Universitario Virgen Macarena | Seville, Andalusia, Spain | Recruiting |
| Hospital Universitari i Politecnic La Fe | Valencia, Spain | Recruiting |
| National Taiwan University Hospital | Taipei, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07438405